Abstract
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have